Please be aware these summaries are produced voluntarily by Biomedical Science students and are their interpretations of the information and findings. This information is reviewed by our Research Analyst Kristina Backlund MMSc. The National Lottery Community Fund and Ionis Pharmaceuticals, Inc have contributed to the funding of the Research Analyst role.
Alex TLC assumes no responsibility or liability for any errors or omissions in the content of these summaries. The information contained in the research summaries is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness, or timeliness. If you are unsure of any of the details within the summaries, please refer to the actual articles or contact info@alextlc.org
We have developed a database of research summaries that include leukodystrophy articles, clinical trials and pharmaceutical press releases to allow our community to easily read about relevant recent research developments.
Please use the drop down boxes below to narrow your search. You can search for condition specific summaries or to view our monthly research summaries which are sent out via email to our community, please select ‘Monthly summary’.
Metachromatic Leukodystrophy (MLD) https://publications.aap.org/pediatrics/article/158/Supplement%202/e2026077357E/208745 Metachromatic leukodystrophy (MLD) is a rare, inherited metabolic disorder affecting approximately one in 100,000 newborns. It results from changes in both copies of the ARSA gene, which reduce the activity of an enzyme needed to break down fatty substances called sulfatides. These substances accumulate in the nervous system, damaging myelin, the […]
GM2 Gangliosidosis https://www.cureus.com/articles/530138 Sandhoff disease is a rare genetic disorder caused by changes in the HEXB gene that prevents certain fatty substances from being broken down properly. Their buildup in nerve cells can gradually affect movement, coordination, and sometimes mental health. Symptoms in later-onset forms can appear like other neurological or psychiatric conditions, which makes […]
Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) https://www.cureus.com/articles/524231 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a rare inherited neurological disorder affecting the brain’s small blood vessels. It is caused by changes in the NOTCH3 gene, which can damage blood vessel walls and reduce blood flow to brain tissue. […]
Adrenoleukodystrophy (ALD) https://www.medrxiv.org/content/10.64898/2026.06.30.26356979v1 X-linked adrenoleukodystrophy (X-ALD) is a rare genetic disorder caused by changes in the ABCD1 gene, leading to the buildup of very long-chain fatty acids in the body. This can affect the brain and adrenal glands, which produce essential hormones. Newborn screening can identify individuals with ABCD1 variants before symptoms appear, although predicting […]
Adrenoleukodystrophy (ALD) https://www.cell.com/molecular-therapy-family/advances/fulltext/S3117-387X(26)00037-6 Cerebral adrenoleukodystrophy (CALD) is a serious, progressive condition that causes inflammation and damage to the brain’s white matter, which supports communication between nerve cells. It is associated with changes in the ABCD1 gene, leading to the accumulation of very long-chain fatty acids. Gene therapy aims to halt disease progression by correcting a […]
Adrenoleukodystrophy (ALD) https://www.cell.com/molecular-therapy-family/advances/fulltext/S3117-387X(26)00156-4 Cerebral adrenoleukodystrophy (cALD) is a form of a rare genetic condition in which very long-chain fatty acids (VLCFA) build up in the body. This can lead to inflammation and damage to myelin, which is the protective covering around nerve fibres in the brain. Two treatments can help slow or stop this damage: […]
Adrenoleukodystrophy (ALD) https://www.minoryx.com/media/european-commission-grants-marketing-authorisation-for-nezglyal%C2%AE-(leriglitazone)-the-first-pharmacological-treatment-approved-for-cerebral-adrenoleukodystrophy-(cald)-a-rare-neurodegenerative-disease European Commission grants marketing authorisation for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease. The therapy is the first approved pharmacological treatment for cALD in the European Union (EU) with approval based on results from the Phase 2/3 NEXUS1 study and additional real-world evidence from […]
Research summary of recent leukodystrophy research and clinical trials, includes article summaries and direct links to websites and articles. To access the summary: Research Summary – October 2026 Please be aware these summaries are produced voluntarily by Biomedical Science students and are their interpretations of the information and findings. This information is reviewed by our Research […]
Mucolipidosis Type IV https://www.cureus.com/articles/464301#! This case report describes a nine‑year‑old boy whose severe corneal clouding (loss of transparency in cornea) and visual loss since birth led to the diagnosis of mucolipidosis type IV (MLIV), a very rare inherited lysosomal storage disorder. Although MLIV usually appears in infants with developmental delay and progressive neurological problems, this […]
Megalencephalic Leukodystrophy with subcortical cysts (MLC) https://www.cureus.com/articles/494833#!/# This case report describes a rare brain disorder called Megalencephalic Leukoencephalopathy with Subcortical Cysts (MLC), also known as Van der Knaap disease. It usually begins in infancy with an enlarged head and slow motor development. However, this case highlights an unusual presentation in a 12‑year‑old boy who developed […]
